Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Doxorubicin Market

Doxorubicin Market Share

Report ID: GMI11168
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Doxorubicin Market Share

The market is highly competitive, with major global pharmaceutical companies and a range of smaller and mid-sized firms striving for dominance. Central to market strategy is the continuous development and launch of innovative formulations and drug delivery systems, employing advanced technologies. Leading players in the industry are heavily investing in research and development to drive these advancements. Additionally, strategic alliances, acquisitions, and mergers have become critical for strengthening market positions and broadening global reach, enabling companies to enhance their product portfolios and penetrate new markets.

Doxorubicin Market Companies

Some of the eminent market participants operating in the doxorubicin industry include:

Accord Healthcare
Baxter International Inc.
Cipla Ltd.
Dr. Reddy's Laboratories Limited
Fresenius SE & Co. KGaA
Johnson and Johnson
Hikma Pharmaceuticals PLC
Lupin Limited
Meiji Holdings Co. Ltd.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Sanofi
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Zydus Lifesciences Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The doxorubicin industry size was valued at USD 1.3 billion in 2023 and is estimated to grow at a 6.3% CAGR from 2024 to 2032 due to usage in the treatment of various cancer types

The injection drug formulation segment in the market is forecasted to reach USD 1.3 billion by 2032 as it is effective against a wide range of cancers, including breast cancer, lymphoma, leukemia, and sarcoma, among others

U.S. doxorubicin industry size will record USD 771.7 million by 2032 led by the presence of a highly developed healthcare infrastructure, including state-of-the-art hospitals and specialized cancer treatment centers.

Accord Healthcare, Baxter International Inc., Cipla Ltd., Dr. Reddy's Laboratories Limited, Fresenius SE & Co. KGaA, Johnson and Johnson, Hikma Pharmaceuticals PLC, Lupin Limited, Meiji Holdings Co. Ltd., Novartis AG, and Pfizer Inc., among others